Loading...
•
Sep 30, 2021
LeMaitre Vascular Q3 2021 Earnings Report
Reported a 5% increase in sales, driven by Artegraft, allografts, and valvulotomes, with a gross margin of 64.8% and an operating income of $9.1 million.
Key Takeaways
LeMaitre Vascular reported Q3 2021 financial results, with sales of $38.4 million, a gross margin of 64.8%, and an operating income of $9.1 million. The company announced a quarterly dividend of $0.11 per share and provided forward guidance for Q4 2021 and full year 2021.
Sales increased by 5% to $38.4 million compared to Q3 2020, with organic growth also at 5%.
Gross margin improved by 250 basis points to 64.8%, attributed to year-ago Artegraft purchase price accounting.
Operating income decreased by 9% to $9.1 million due to a 24% increase in operating expenses.
Net income decreased by 13% to $6.5 million, with earnings per diluted share at $0.30, a 19% decrease.
Forward Guidance
LeMaitre Vascular provided guidance for Q4 2021 with sales between $39.0 million and $41.0 million, gross margin of 66.3%, operating income between $8.3 million and $9.7 million and EPS between $0.29 and $0.34. Full year 2021 guidance includes sales between $153.9 million and $155.9 million, gross margin of 65.8%, operating income between $36.5 million and $37.8 million, and EPS between $1.26 and $1.31.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...